scholarly journals Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer

Cancer Cell ◽  
2017 ◽  
Vol 31 (4) ◽  
pp. 532-548.e7 ◽  
Author(s):  
Xiaoju Wang ◽  
Yuanyuan Qiao ◽  
Irfan A. Asangani ◽  
Bushra Ateeq ◽  
Anton Poliakov ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Gene Fusion ◽  
Fusion Product ◽  
Peptidomimetic Inhibitors

scholarly journals Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer

Cancer Cell ◽  
2017 ◽  
Vol 31 (6) ◽  
pp. 844-847 ◽  
Author(s):  
Xiaoju Wang ◽  
Yuanyuan Qiao ◽  
Irfan A. Asangani ◽  
Bushra Ateeq ◽  
Anton Poliakov ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Gene Fusion ◽  
Fusion Product ◽  
Peptidomimetic Inhibitors

Combination Therapies Using Metformin and/or Valproic Acid in Prostate Cancer: Possible Mechanistic Interactions

2019 ◽  
Vol 19 (5) ◽  
pp. 368-381 ◽  
Author(s):  
Linh N.K. Tran ◽  
Ganessan Kichenadasse ◽  
Pamela J. Sykes
Keyword(s):  
Prostate Cancer ◽  
Valproic Acid ◽  
Androgen Receptor ◽  
Gene Fusion ◽  
Combination Therapies ◽  
Slowing Down ◽  
Castration Resistant ◽  
Local Pca ◽  
End Stage ◽  
Fusion Products

Prostate cancer (PCa) is the most frequent cancer in men. The evolution from local PCa to castration-resistant PCa, an end-stage of disease, is often associated with changes in genes such as p53, androgen receptor, PTEN, and ETS gene fusion products. Evidence is accumulating that repurposing of metformin (MET) and valproic acid (VPA) either when used alone, or in combination, with another therapy, could potentially play a role in slowing down PCa progression. This review provides an overview of the application of MET and VPA, both alone and in combination with other drugs for PCa treatment, correlates the responses to these drugs with common molecular changes in PCa, and then describes the potential for combined MET and VPA as a systemic therapy for prostate cancer, based on potential interacting mechanisms.

scholarly journals A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis

2007 ◽  
Vol 20 (4) ◽  
pp. 467-473 ◽  
Author(s):  
Jacques Lapointe ◽  
Young H Kim ◽  
Melinda A Miller ◽  
Chunde Li ◽  
Gulsah Kaygusuz ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Molecular Diagnosis ◽  
Fusion Product

784 TMPRSS2-ERG GENE FUSION DEFINES A METASTATIC PHENOTYPE OF PROSTATE CANCER

2009 ◽  
Vol 8 (4) ◽  
pp. 316
Author(s):  
S. Perner ◽  
M. Svensson ◽  
R. Hossain ◽  
J. Day ◽  
J. Groskopf ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Gene Fusion ◽  
Metastatic Phenotype

scholarly journals Significance of the TMPRSS2:ERG gene fusion in prostate cancer

2017 ◽  
Vol 16 (4) ◽  
pp. 5450-5458 ◽  
Author(s):  
Zhu Wang ◽  
Yuliang Wang ◽  
Jianwen Zhang ◽  
Qiyi Hu ◽  
Fan Zhi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Gene Fusion

scholarly journals The TMPRSS2–ERG Gene Fusion Blocks XRCC4-Mediated Nonhomologous End-Joining Repair and Radiosensitizes Prostate Cancer Cells to PARP Inhibition

2015 ◽  
Vol 14 (8) ◽  
pp. 1896-1906 ◽  
Author(s):  
Payel Chatterjee ◽  
Gaurav S. Choudhary ◽  
Turkeyah Alswillah ◽  
Xiahui Xiong ◽  
Warren D. Heston ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Cells ◽  
Gene Fusion ◽  
Nonhomologous End Joining ◽  
Parp Inhibition ◽  
Prostate Cancer Cells ◽  
End Joining

scholarly journals Inflammation-Induced Oxidative Stress Mediates Gene Fusion Formation in Prostate Cancer

Cell Reports ◽  
2016 ◽  
Vol 17 (10) ◽  
pp. 2620-2631 ◽  
Author(s):  
Ram S. Mani ◽  
Mohammad A. Amin ◽  
Xiangyi Li ◽  
Shanker Kalyana-Sundaram ◽  
Brendan A. Veeneman ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Prostate Cancer ◽  
Gene Fusion
Sign in / Sign up

Export Citation Format

Share Document